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Abstract
De novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neuro-
logical syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic car-
diomyopathy. Using whole-exome sequencing, we identified a dominantly inherited heterozygous variant c.1064G>A
(p.G355D) in ATAD3A in a mother presenting with hereditary spastic paraplegia (HSP) and axonal neuropathy and her son
with dyskinetic cerebral palsy, both with disease onset in childhood. HSP is a clinically and genetically heterogeneous dis-
order of the upper motor neurons. Symptoms beginning in early childhood may resemble spastic cerebral palsy. The function
of ATAD3A, a mitochondrial inner membrane AAA ATPase, is yet undefined. AAA ATPases form hexameric rings, which are
catalytically dependent on the co-operation of the subunits. The dominant-negative patient mutation affects the Walker A
motif, which is responsible for ATP binding in the AAA module of ATAD3A, and we show that the recombinant mutant
ATAD3A protein has a markedly reduced ATPase activity. We further show that overexpression of the mutant ATAD3A frag-
ments the mitochondrial network and induces lysosome mass. Similarly, we observed altered dynamics of the mitochondrial
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network and increased lysosomes in patient fibroblasts and neurons derived through differentiation of patient-specific
induced pluripotent stem cells. These alterations were verified in patient fibroblasts to associate with upregulated basal
autophagy through mTOR inactivation, resembling starvation. Mutations in ATAD3A can thus be dominantly inherited and
underlie variable neurological phenotypes, including HSP, with intrafamiliar variability. This finding extends the group of
mitochondrial inner membrane AAA proteins associated with spasticity.
Introduction
Hereditary spastic paraplegia (HSP) is a disorder of the upper motor
neurons leading to spastic weakness of the lower limbs (1).
Symptoms can be present at birth, or develop gradually during
childhood or adulthood, and intrafamilial clinical variability is
often observed (2). Non-complicated HSP presents typically with
pyramidal signs and bladder dysfunction, whereas complicated
forms may include cerebellar or extrapyramidal signs, epilepsy,
cognitive impairment and axonal neuropathy (3). Cerebral palsy
(CP) is a non-progressive developmental disorder of the fetal or in-
fant brain that causes problems with movement and posture, and
can include spasticity, dyskinesia or ataxia (4). In most cases, CP re-
sults from cerebral insults occurring during pregnancy or in the
perinatal period, although a substantial genetic contribution has
also been proposed (5). Spastic diplegic CP may not be easily distin-
guishable from HSP particularly when family history is negative (6).
The known HSP genes take part in a range of cellular activ-
ities such as microtubule dynamics, endoplasmic reticulum
morphogenesis, lysosomal and mitochondrial functions and
lipid metabolism (1). Of the mitochondria-mediated HSP, SPG7
is the best studied disease gene (7). It encodes paraplegin, a sub-
unit of an AAA (ATPase associated with diverse cellular activ-
ities) protease of the inner mitochondrial membrane. AAA
proteins typically form hexameric ring complexes that are cata-
lytically active only in the fully assembled state, and show co-
operativity among the six subunits (8). Paraplegin forms hetero-
oligomers with another mitochondrial AAA protein AFG3L2,
which is associated with early-onset spasticity with ataxia (9).
A recurrent de novo mutation in ATAD3A (ATPase family
AAA-domain containing protein 3A) leading to the amino acid
change p.R528W was recently described in patients with global
developmental delay, hypotonia, spasticity, optic atrophy, axo-
nal neuropathy, and hypertrophic cardiomyopathy (10).
ATAD3A is a nuclear-encoded mitochondrial inner membrane
ATPase with functions implicated in the control of mitochon-
drial dynamics (11), cholesterol channeling (12), and the main-
tenance of the mitochondrial DNA-protein complexes, the
nucleoids (13–15). ATAD3A is anchored to the mitochondrial
inner membrane with the N-terminus having contact sites with
the outer membrane (11). Its C-terminal AAA ATPase domain is
located in the mitochondrial matrix and contains the conserved
Walker A and B motifs for ATP binding and ATPase activity, re-
spectively (16,17). Expression of a Walker A mutant incapable of
ATP binding resulted in fragmentation of the mitochondrial net-
work in a glioblastoma cell line (11). Expression of the
Drosophila mutant equivalent to the human de novo mutation
R528W affected survival in flies, except when driven only to the
muscles, where it resulted in a reduction in the number of mito-
chondria, presenting with small size and aberrant cristae, and
in increased amounts of autophagic intermediates (10).
Induction of mitophagy, the autophagy of mitochondria, was
also reported in a R528W patient’s fibroblasts, based on trans-
mission electron microscopy (10). The authors concluded that
the de novo mutation was likely to have a strong dominant-
negative effect.
We report here dominant transmission of an ATPase-
deficient Walker A mutation in ATAD3A, presenting as heredi-
tary spastic paraplegia and tetraplegia within the same family.
Results
Clinical description
Patient II:1 is a 35-year-old female with congenital lower leg
spasticity (Fig. 1A and C). She was born to healthy parents of a
normal pregnancy, and without perinatal problems. The pa-
tient’s father died at the age of 45 of an unknown cause, follow-
ing excessive alcohol consumption. The family has origins in
Northern Finland, Moldova and Russia.
The patient learned to speak and was able to stand with sup-
port around one year of age, and started to walk short distances
at the age of three years. Because of her lower leg spasticity,
both her Achilles tendons have been operated at an early age.
Since childhood the patient has had strong myopia with a level
of minus 10 diopters. She had no learning difficulties at school,
and performed well academically. In adulthood, the spasticity
has remained relatively stable. The patient has been otherwise
healthy, apart from a goiter that was operated at the age of 33.
Patient II:1’s brain MRI was normal. Her spinal cord seemed
thin and atrophic, without any focal signs or signals (Fig. 1B). An
electroneuromyography (ENMG) showed moderate chronic
motor and sensory axonal neuropathy. A blood test showed the
patient’s thyroid function to be normal, her creatine kinase was
100 IU/l (reference range 35–210 IU/l), and lactate 0.7 mmol/l (ref-
erence range 0.5–2.2 mmol/l). Blood pyruvate was slightly
increased at 71 mmol/l (reference range 40–70 mmol/l). A cardiac
examination performed at the age of 18 was normal.
In a neurological examination at the age of 35 the patient
was found to be 158 cm tall with a BMI of 18. She walked with
two sticks aided by one person. She had no problems in speech,
cognition, or eye movements. No ptosis was noted but she had
significant photophobia that restricted eye opening. The muscle
strength and tone of her upper limbs were normal. In her lower
limbs, she had strong spasticity and deformity in her knees and
ankles (Fig. 1A). Muscle strength in her lower limbs was clearly
reduced especially distally, but overcame gravity. Tendon
reflexes were lost at the ankles, but found at the knee level and
in the arms. Sensory testing was normal apart from abnormal
proprioception in the lower legs. Babinski and Hoffman signs
were positive.
The patient’s only child (III:1, Fig. 1C) is a 3.5-year-old male.
He was born at gestational week 39 by cesarean section because
of his mother’s condition. His Apgar scores were 8/9 and birth
weight 3310g. He had no perinatal problems.
The son was sent to hospital at the age of 4 months due to
spasticity in his lower extremities. His plasma creatine kinase
value was 180 U/l (reference range 50–270 U/l), alanine aminotrans-
ferase 20 U/l (reference range< 40 U/l), ammonia 57 mmol/l (refer-
ence range< 50 mmol/l) and lactate 2.6 mmol/l (reference range 0.5–
2.2 mmol/l). An EEG was performed at the age of 9 months and a
brain and cervical spine MRI at the age of 12 months with normal
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results. At the age of 3.5 years the patient had dyskinetic cerebral
palsy with severe spasticity both in his upper and lower extrem-
ities. He was not able to speak, sit or stand, and he could only crawl
by pulling himself forwards with his arms or roll on the floor. An
ENMG was not performed. His classification in Gross Motor
Function Classification System was IV-V and Communication
Function System Classification IV-V. Furthermore, he was found to
have heavy eyelids giving the impression of ptosis. Similar to his
mother, he had lost his lateral eyelashes at about the age of 6
months, and he had photophobia.
Exome sequencing and verification of the ATAD3A
variant
To identify the genetic cause of the dominantly inherited
condition in this family, we performed whole-exome
Figure 1. Family with ATAD3A Walker A mutation. (A) Patient II-1 (35-year-old, female) has deformity in the lower extremities. (B) Magnetic resonance imaging of pa-
tient II-1 shows thinning and atrophy of the spinal cord (arrows). (C) Pedigree of the investigated family. Grandparents (I:1 and I:2) were not affected. Patient II:1 and
her son III:1 have the heterozygous c.1064G>A variant in ATAD3A. (D) Sanger sequencing of the ATAD3A c.1064G>A variant in the samples of the family members I:2,
II:1 and III:1. (E) Schematic presentation of the human ATAD3A protein and conservation of the Walker A motif. ATAD3 proteins contain two coiled-coil domains (Cc1
and Cc2), and an ATPase domain with Walker A (WA) and Walker B (WB) motifs. The glycine in the Walker A motif affected by the patient mutation G355D (arrow) is in-
variant in ATAD3 proteins between species, in human mitochondrial proteins with AAA modules and in the human ATAD family. The invariant lysine K358 is also
indicated by an arrow. (F) In silico modeling of the G355D mutation suggests that the substitution of glycine 355 to aspartate changes the affinity of the substrate-bind-
ing site for ATP. Walker A motif is shown in red. (G) ATPase activities of the recombinant ATAD3A proteins (WT, patient mutant G355D and Walker dead K358A) as-
sessed by the amount of phosphate liberated as described in the materials and methods. The measurements of five independent experiments are shown, the mean is
indicated. The reactions were performed in the presence of 8 nM of ATAD3A protein. In the combined reactions of wild type and G355D mutant proteins 8 nM of each
ATAD3A variant was used.
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sequencing on the DNA samples of the affected mother and
son. Filtering for variants in known HSP genes did not reveal
potential disease-causing variants. A combined analysis of
the two exomes resulted in 12 heterozygous single nucleo-
tide variants of interest (Supplementary Material, Table S1).
Of these the variant c.1064G>A [p.G355D] (GenBank:
NM_001170535.1; chr1:1459319) in ATAD3A caught our atten-
tion. It was not present in publicly available databases, and
had a Combined Annotation Dependent Depletion (CADD)
score of 24.3. We confirmed by Sanger sequencing that the af-
fected mother (II:1) and son (III:1) were heterozygous for the
variant, whereas the grandmother (I:2) did not carry the vari-
ant (Fig. 1D). The grandfather’s (I:1) DNA sample was not
available for the study.
The amino acid change from glycine to aspartate affects the
Walker A motif of the ATPase (Fig. 1E). This phosphate-binding
(P-) loop has a consensus pattern of G-X(4)-GK-[TS] (18), with X
denoting any amino acid, and the invariant lysine being crucial
for nucleotide-binding and hydrolysis. However, the second gly-
cine of the motif GPPGTGKTL is invariant in all ATAD3 homo-
logues from human to Arabidopsis, as well as in other human
mitochondrial AAA proteins (Fig. 1E). A structural in silico ana-
lysis of the mutant suggested that the G355D change has no ef-
fect on protein stability, P-loop fold or interactions between
K358 and the b- and c-phosphates of ATP, which are critical for
ATPase activity. However, the mutation introduces a negative
charge at a distance of less than 4 A˚ from the c-phosphate of an
incoming ATP in the substrate-binding site (Fig. 1F), which is
predicted to result in decreased affinity for ATP. We expressed
and purified C-terminal recombinant ATAD3A proteins contain-
ing the mitochondrial matrix-localizing ATPase domain
(Supplementary Material, Fig. S1), and measured the ATPase
activities of wild type and mutant proteins containing the
amino acid changes G355D or K358A (the invariant lysine of the
Walker A motif). As predicted, the ATPase activities of the
Walker A mutant proteins were markedly reduced in compari-
son to the wild type recombinant protein (Fig. 1G). Membrane
AAA ATPases form hexamers that are catalytically dependent
on the co-operation of the subunits. The ATP-binding site in
each subunit is located at the interface of the neighboring sub-
unit, and the ATP hydrolysis in one subunit triggers conform-
ational changes in the neighboring subunit leading to a
unidirectional cycle of ATP hydrolysis within the hexameric
ring. If ATP hydrolysis is blocked in one subunit the entire pro-
tein is rendered nonfunctional (19). Similarly to other mem-
brane AAA ATPases, ATAD3A is also proposed to form
oligomers (11). We thus measured the ATPase activity of wild
type ATAD3A mixed with an equal concentration of G355D, and
found, as predicted, that the reduced ATP binding of the mutant
ATAD3A had a strong dominant-negative effect on the ATPase
function (Fig. 1G).
Overexpressed G355D ATAD3A induces mitochondrial
fragmentation
Previously, overexpression of a mutant affecting the critical ly-
sine, K358, in the Walker A motif of ATAD3A was shown to in-
duce fragmentation of the mitochondrial network in cultured
U373 glioblastoma cells (11). We therefore tested whether the
G355D mutant also induced fragmentation when overex-
pressed. We expressed the wild type ATAD3A, and the K358R
and G355D mutants in primary human fibroblasts, together
with mitochondria-targeted green fluorescent protein
(mitoGFP), and counted the percentages of transfected cells that
displayed fragmented mitochondria (Means6SEM of four inde-
pendent counts of fragmented cells 0.45%60.45 (mitoGFP),
19.5%62.09 (WT), 37.0%6 3.45 (K358R), 32.26 3.23 (G355D), Fig.
2A and C, Supplementary Material, Fig. S2). Control cells with
only mitoGFP transfected had normal elongated mitochondria,
whereas overexpression of wild type ATAD3A (P¼ 0.0013 com-
pared to mitoGFP) or the mutant forms (P¼ 0.0001 for K358R and
P¼ 0.0001 for G355D, compared to mitoGFP) induced mitochon-
drial fragmentation in a proportion of transfected cells. Both
mutants induced fragmentation significantly more frequently
than the overexpression of the wild type ATAD3A (P¼ 0.003 for
K358R and P¼ 0.028 for G355R, compared to WT, Fig. 2C). As
tested by Western blotting, all transfected ATAD3A constructs
were expressed at similar levels (Fig. 2B). We also detected
increased amounts of lysosomes by LysoTracker staining in the
cells containing fragmented mitochondria (Fig. 2D).
Basal autophagy is upregulated in patient fibroblasts
Instead of investigating the overexpression cells further, we
focused on the patient’s fibroblasts with endogenous expression
of the mutant ATAD3A. By using immunocytochemistry of
mitochondrial markers and by electron microscopy, we de-
tected increases in elongated, unbranched mitochondria in the
patient’s cells (Fig. 3A and E). While ATAD3A protein levels were
normal in patient cells, we noticed an increase in the ratio of re-
spiratory complex IV and II subunits, and a reduction in the
level of the mitochondrial fission protein Drp1 in patient cells
compared to controls (Fig. 3B). Also, patient mitochondria were
hyperpolarized (Supplementary Material, Figs 3 and 5), which
has been shown to be a feature of hyperfused mitochondria
(20). In addition, large amounts of lysosomes were seen in pa-
tient cells by staining with LysoTracker Green (Fig. 3C), and by
electron microscopy (Fig. 3E). Quantification of the Lysotracker
signal by flow cytometry confirmed the increase of lysosomes in
patient fibroblasts compared to controls (Fig. 3F, Supplementary
Material, Fig. S4). We then used Western blotting to inspect
markers related to autophagy in patient cells under fed and
serum starved conditions and when autophagy was inhibited
with bafilomycin (Fig. 3D). The levels of p62, which is degraded
during autophagic flux, were found to be constitutively low in
patient cells, suggestive of upregulated basal autophagy (21). To
investigate the upstream signaling events leading to the lyso-
somal increase, we assessed the phosphorylation of the
autophagy-initiating kinase ULK1 and the ribosomal protein S6,
both of which are targets of the autophagy regulator mTOR
(22,23). ULK1 was dephosphorylated at Ser757 in patient cells
compared to controls under fed and starved conditions (Fig. 3D)
(24). This demonstrated that mTOR was inhibited in patient
cells, thereby suggesting that AMPK promoted the increase in
macroautophagy via ULK1 (24). Levels of total mTOR and phos-
phorylated mTOR in patient cells were comparable to those in
controls. S6 phosphorylation at Ser235/236 was decreased in pa-
tient cells compared to controls (Fig. 3D), suggestive of a general
downregulation of protein synthesis. The patterns of all of these
markers in patient cells in all conditions were remarkably simi-
lar to the control cells under starvation, highly suggesting that
the mutant cells were in a starvation-like state. The elongation
of mitochondria is likely a consequence of the upregulated
autophagy, since mitochondrial elongation during autophagy
has been shown to spare them from degradation and sustain
cell viability (20). Collectively, these data indicate that the
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mutant ATAD3A induced mitochondrial elongation in patient
fibroblasts, which was associated with mTOR inhibition leading
to the induction of basal macroautophagy.
Altered mitochondrial network and lysosome content in
patient neurons
To study the pathology of the ATAD3A mutation in neurons, we
reprogrammed patient’s fibroblasts into pluripotent stem cells
and differentiated those into neurons (25) (Supplementary
Material, Fig. S6). The differentiation process of the patient cells
was similar compared with the controls, and morphologically
patient neurons appeared indistinguishable from controls. The
neuronal cultures were composed of a heterogeneous cell popu-
lation, of which approximately 30%–40% stained positive for a
neuronal marker TUJ1. Confocal microscopic analysis of neu-
rons immunostained for ATAD3A showed an altered appear-
ance of the mitochondrial network in patient neurons
compared to controls (Fig. 4A). In particular, more uniform
staining was detected in the extensions of patient neurons,
which may indicate elongated mitochondria. On the other
hand, electron microscopy also revealed fragmented mitochon-
dria (Fig. 4D, Supplementary Material, Fig. S7), and perinuclear
accumulations of mitochondria were observed by confocal mi-
croscopy (Fig. 4A). These findings suggested that patient neu-
rons had unbalanced dynamics of mitochondria. Lysotracker
staining and electron microscopy showed an increase in
Figure 2. Overexpressed Walker A mutants induce mitochondrial fragmentation. (A) Fluorescent microscopy images of primary human fibroblasts transfected with
mitochondria-targeted green fluorescent protein (mito-GFP) alone or together with wild type ATAD3A (WT), or ATAD3A Walker A mutants K358R or G355D. ATAD3A
immunocytochemistry with ATAD3 antibody is shown. See Supplementary Material, Fig. S2 for merged images. (B) Western blotting shows equal levels of ATAD3A in
cells transfected with WT, or the K358R or G355D mutant ATAD3A. GAPDH is shown as a loading control. (C) Quantification of the transfected cells displaying mito-
chondrial fragmentation in the experiment shown in A. Fragmented cells were manually counted four independent times in a randomized blinded manner (n¼157
transfected cells counted for each genotype). Means6SEM are shown. *P<0.05, **P<0.005, one-way ANOVA with Bonferroni correction. (D) Merged images of fibro-
blasts transfected with WT, K358R or G355D ATAD3A plasmids, and stained with LysoTracker Green (lyso-Green) for lysosomes and MitoTracker Red (mito-Red) for
mitochondria. Cells with fragmented mitochondrial networks show increased staining with LysoTracker Green. Scale bars¼20mm.
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lysosomes in patient neurons compared with controls (Fig. 4B,
Supplementary Material, Fig. S6). No changes in ATAD3A pro-
tein level (Fig. 4C) or mtDNA copy number (Fig. 4E), nor mtDNA
deletions (not shown) were observed in samples taken from the
mixed neuronal cultures.
Discussion
Our report extends the phenotypes caused by ATAD3A muta-
tions to early-onset HSP, and dyskinetic CP, and shows that
disease-causing ATAD3A mutations can be dominantly
inherited. ATAD3A should be thus considered a candidate gene
in sporadic or dominant HSP. We could not confirm whether the
ATAD3A mutation was de novo in our patient II:1 as her father’s
DNA sample was not available for study. The phenotypes
described recently in patients with the de novo R528W mutation
have some overlap with our patients, as spasticity and periph-
eral neuropathy were reported in four of five patients (10).
However, neither of our patients had optic atrophy or hyper-
trophic cardiomyopathy, and our patient II:1 did not have devel-
opmental delay or intellectual disability. A diagnostic clue may
be provided by photophobia, which both of our patients had.
Figure 3. Mitochondrial elongation and upregulation of autophagy in patient fibroblasts. (A) Primary patient skin fibroblasts show an elongated mitochondrial morph-
ology when compared with control cells. Mitochondria were immunolabeled with Tom20 (green) and ATAD3A (red) antibodies. (B) ATAD3A protein level is unchanged
in patient (P) cells, but levels of Drp1 are reduced and the relative amounts of respiratory chain complex subunits are altered compared to controls (C) cells. (C) Live cell
imaging shows an increase in the number of lysosomes (lyso-Green) and mitochondrial elongation (mito-Red) in patient neurons. Scale bars¼20mm. (D)
Phosphorylation and levels of mTOR mediated basal autophagy markers ULK1 (Ser757) and S6 (Ser235/236) are altered in patient (P) cells compared to controls (C) under
fed and starved conditions and when autophagy is inhibited (V, vehicle; B, bafilomycin) (E) Electron micrographs show large amounts of lysosomal structures (black
arrow, upper panel) and unbranched elongated mitochondria (black arrow, lower panel) in the patient fibroblasts. (F) Lysosomal quantification by flow cytometry,
(Ncontrol¼24459, Npatient¼19517) ***P<0.0001, Student’s t-test.
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Our family also demonstrates intrafamilial phenotypic variabil-
ity, which is often seen in association with HSP (2).
We showed that the patient mutation, changing glycine to
aspartate in the ATP-binding Walker A motif, markedly reduced
the ATPase activity of ATAD3A in vitro, but did not affect the
steady-state amount of the ATAD3A protein in patient cells.
Furthermore, we showed that the mutant protein mixed with
the wild type protein abolished the activity of the wild type en-
zyme. Thus the molecular defect in our patients is directly
related to the loss of ATPase activity, which is mediated by a
dominant-negative effect on the oligomeric protein (11). Other
mitochondrial AAA proteins such as paraplegin function as
hexameric rings (26). Their chaperone-like and proteolytic activ-
ities have important roles in mitochondrial protein quality con-
trol, but in addition to the AAA module, they also have a
conserved proteolytic domain that is not present in ATAD3A.
Mammalian ATAD1, which also lacks the proteolytic domain,
has recently been assigned a role in the mitochondrial protein
quality control system, where it mediates the degradation of
tail-anchored ER proteins that have been mislocalized to mito-
chondria (27). The mitochondrial target of the ATPase activity of
ATAD3A is, however, still not known.
Human ATAD3, which refers to the two mitochondrial paral-
ogs, ATAD3A and ATAD3B, has been implicated in the mainten-
ance of mitochondrial nucleoids and their membrane
attachment (13–15). In our patient neurons with the ATAD3A
defect, we did not observe changes in the quality or quantity of
mitochondrial DNA. It is not yet clear what contribution each
ATAD3 paralog has in cells and different tissue types. One study
found ATAD3B to function as dominant negative for the ubiqui-
tous ATAD3A (28), whereas ATAD3B has been found highly ex-
pressed in cells with proliferative potential, and frequently in
Figure 4. Increased lysosomes in patient-specific neurons. (A) Neurons derived through differentiation of ATAD3A patient’s induced pluripotent stem cells show
altered appearance of the mitochondrial network and ATAD3 immunostaining compared to control neurons. Neurons were identified with TUJ1 (green), and labelled
with ATAD3 antibody (red). The white arrows point to the neuronal soma and an extension, which are enlarged on the right. (B) Increased lysosomal structures are
seen in patient neurons as stained with Lysotracker Green. (C) Patient (P) neuronal cultures have a comparable ATAD3A protein level to control (C) cells. (D) Electron
micrographs show large amounts of lysosomal structures (black arrow) in the patient neurons. White arrows point to mitochondria. (E) The mitochondrial DNA copy
number was comparable to control cells in the patient neuronal culture, as determined by quantitative PCR. NS, non-significant, Student’s t-test.
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cancer cells (29). Mice only have one Atad3 gene, and its knock-
out is embryonic lethal (30).
ATAD3 has been suggested to locate to contact points of the
outer and inner mitochondrial membranes (23), and to be en-
riched in mitochondria associated membranes (MAM) (12,13),
implying contact with the endoplasmic reticulum (29). The ER
contacts are important for transit of newly made proteins, lipids
and calcium. As a genetically heterogeneous disease, HSP is
associated with several cellular pathways, such as abnormal-
ities in axonal transport, ER morphology, mitochondrial func-
tion, protein misfolding leading to ER stress, vesicle formation
and membrane trafficking, and lipid metabolism (31). The
mechanism of ATAD3A in neurological diseases could be linked
to several of these pathways. It is, however, interesting that par-
aplegin, AFG3L2 and HSP60, all important for mitochondrial pro-
tein homeostasis, have also been connected to spasticity
phenotypes (7,9,32). This could imply that ATAD3A may func-
tion in mitochondrial protein quality control perhaps through a
similar mechanism as ATAD1. On the other hand, paraplegin
also contributes to the assembly of the mitochondrial ribosome
(33), and ATAD3 has been reported to bind the mitoribosome
and to be required for mitochondrial protein synthesis (15). Our
observation that the ratio of respiratory chain complex IV and II
subunits was increased in patient fibroblasts suggests a defect
related to mitochondrial gene expression, typically seen as a re-
duction in complex IV and a compensatory increase in complex
II, which in contrast to the other complexes does not contain
mtDNA-encoded subunits. ATAD3 is also needed for maintain-
ing cristae structure (13), the loss of which will compromise the
respiratory chain. Therefore, there are multiple possibilities for
how ATAD3A dysfunction could cause HSP.
In our patient’s fibroblasts, the reduced ATPase activity of
ATAD3A was associated with changes in mitochondrial morph-
ology, in particular as highly elongated mitochondria. In patient
neurons elongated mitochondria were also observed as well as
perinuclear accumulations of mitochondria. These results sug-
gested that the dynamics of mitochondria was altered. ATAD3
knockdown has previously been found to result in aberrant
mitochondrial morphology, most notably a collapse of mito-
chondrial membrane structure (13). Our overexpression experi-
ments in primary fibroblasts indicated that the high-level
expression of ATPase deficient mutants and also the wild type
ATAD3A caused mitochondrial fragmentation. Collectively, the-
se results suggest that a proper amount of functional ATAD3A
is needed to keep the mitochondrial dynamics in balance.
We found the altered mitochondrial dynamics to be associ-
ated with greatly increased lysosome mass in overexpression
cells, patient fibroblasts and neurons. Previously, the electron
micrographs of fibroblasts from a patient with the de novo
R528W mutation were reported to show increased mitophagic
vesicles (10), and ATAD3 knockdown to induce autophagy (34).
We studied the patient fibroblasts in more detail for autophagy
induction, and found the markers to indicate the induction of
basal autophagy in these cells. In particular the combination of
low levels of p62, the dephosphorylated ULK1-Ser757 and the
reduced phosphorylation of S6, indicated inactivity of mTOR, re-
sulting in a phenotype resembling cells undergoing starvation.
Interestingly, mitochondria are known to elongate in response
to starvation-induced autophagy (20), which is thought to pro-
tect them from autophagic degradation because of their
enhanced ability to maintain ATP production. In fact, mitochon-
drial elongation is required to prevent starvation-induced cell
death (20). The findings in our patient cells suggest that a simi-
lar process has been initiated by the ATAD3A mutation. mTOR
is inhibited by oxidative stress (35), and could perhaps induce
autophagy in response to reactive oxygen species produced in
response to the mutant ATAD3A. Alternatively, due to its loca-
tion at ER-mitochondria junctions and its resemblance to chap-
erone proteins, a dysfunctional ATAD3A could induce ER stress
which, especially in relation to the unfolded protein response,
can trigger mTOR-mediated autophagy (36). ATAD3A appears to
have a role as an anti-autophagic factor, but whether it is dir-
ectly or indirectly involved in the regulation of mitochondrial
dynamics and/or autophagy, remains to be studied.
In conclusion, we describe an ATAD3A mutation that is
dominantly inherited in a family with HSP. Although further
genetic evidence from additional families is needed to verify the
association of ATAD3A and dominant HSP, we provide clear evi-
dence for the molecular mechanism of this ATAD3A mutation
and describe intracellular consequences of ATPase deficiency of
ATAD3A. Further studies of this interesting mitochondrial AAA
protein are warranted to understand its role in neurological
diseases.
Materials and Methods
Patients and controls
Patient and control samples were taken according to the
Declaration of Helsinki, with informed consent. The study was
approved by the review board of the Helsinki University
Hospital. The skin fibroblasts used in the study were derived
from patient II:1.
DNA sequencing
For whole-exome sequencing, the exome targets of the patients’
DNA were captured with the Agilent Clinical Research Exome
followed by Illumina HiSeq 2500 sequencing. The reads were
aligned to the hg19 reference genome, using the Burrows-
Wheeler Alignment tool and the variants called with the
SAMTOOLS package (37,38). We annotated the variants with the
ANNOVAR program and added annotations for predicted dele-
teriousness (Combined Annotation Dependent Depletion
(CADD)), and population frequency of variants (Exome
Aggregation Consortium (ExAc)). The variants were filtered by
criteria: 1) absent from dbSNP build 138 (https://www.ncbi.nlm.
nih.gov/SNP/), 2) absent from the Exome ExAC database of
60,000 unrelated individuals, 3) absent in an in-house data-
base of 277 exomes, 4) predicted to change the amino acid se-
quence or splice site, and 5) minimum Combined Annotation
Dependent Depletion (CADD) score of 10. The identified variant
in ATAD3A was Sanger sequenced using the following genomic
primers: 5’-GGGATAGATAGGCTGCCCCT-3’ and 5’-AGGGGAGA
CAGAGCAGATGT-3’.
In silico analysis
To access the structural and functional outcome of the G355D
change in silico, the AAA domain of ATAD3A was modeled using
the homologues AAA domain of the bacterial AAA protease
FtsH as a template (PDB id 1lv7). The sequence identity and
similarity between AAA domains of these two proteins are
20.8% and 39.4%, respectively. An ATP molecule was docked
into the ATP-binding site of the model using the Discovery stu-
dio 4.5 software (BIOVIA).
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Purification of recombinant ATAD3A protein
A DNA fragment encoding the ATAD3A c-terminus (264AA-
568AA) was cloned into the pGEX-6P-2 vector using the BamHI
and XhoI restriction sites. This clone was used to generate the
ATAD3A G355D and K358R mutant pGEX-6P-2 constructs.
Rosetta 2(DE3) E.coli cells were transformed with the pGEX-6P-2-
ATAD3A expression plasmid. An overnight culture was grown
at 37 C and used to inoculate 3 liters of TB medium. The culture
was grown at 37 C to an OD600¼ 0.8, then the temperature was
reduced to 18 C and expression induced with 0.5 mM IPTG for
20 h. Cells were harvested by centrifugation at 5.000 x g for
15 min at 4 C. Pellets were first washed and then resuspended
in ice-cold lysis buffer (25mM HEPES pH 7.4, 200 mM NaCl, 5 mM
b-mercaptoethanol, 10% glycerol, protease inhibitors (10 lM
AEBSF, 2 lM Bestatin, 1 lM Pepstatin, 2 lM E64) and 0.2 mg/ml
DNase. Next, cells were disrupted using the Constant cell dis-
ruption system (Constant Systems Ltd). Cell lysates were clari-
fied by centrifugation at 25.000 x g for 60 min and incubated
with glutathione sepharose beads for 2.5 h at 4 C (GE
Healthcare). The beads were washed with 50 ml buffer A (25mM
HEPES pH 7.4, 200 mM NaCl, 5 mM EDTA, 5 mM b-mercaptoetha-
nol, 5% glycerol, protease inhibitors and 0.05% TritonX100), fol-
lowed by a 50 ml buffer B wash (25 mM HEPES pH 7.4, 200 mM
NaCl, 5 mM b-mercaptoethanol and 5% glycerol), followed by a
10 ml buffer C wash (25mM HEPES pH 7.4, 100 mM KCl, 1 mM
ATP, 1 mM MgCl2, 5 mM b-mercaptoethanol, 5% glycerol) and fi-
nally by a 10 ml buffer D wash (25mM HEPES pH 7.4, 50 mM
NaCl, 5 mM b-mercaptoethanol, 5% glycerol). The GST-ATAD3A
fusion protein was eluted with buffer D supplemented with
40 mM reduced glutathione. GST-ATAD3A-containing fraction
were combined and loaded on a 1 ml heparin column (GE
Healthcare). After washing the column with buffer D, buffer D
containing 1.2M NaCl was used to elute the protein. Fractions
containing GST-ATAD3A were combined and incubated with
1:25 weight/weight homemade HIS-tagged HRV 3C protease
(Umea˚ Protein Expertise Platform) in the same buffer overnight.
Next day the samples were loaded on a Ni-NTA agarose
(Qiagen) to remove the HRV 3C protease. The next day the pro-
tein was passed through a PD-10 column (GE Healthcare) and
untagged ATAD3A protein was purified on further on a heparin
column as described above. Peak fractions were frozen in liquid
N2 and stored at80 C.
ATPase assay
The ATPase assay was performed in a buffer containing 50 mM
Tris-HCl (pH 8.0), 70 mM NaCl/KCl, 2 mM MgCl2, 1 mM ATP and
1 mM DTT in a reaction volume of 50 ll. Reaction mixtures con-
taining 8 nM ATAD3A were incubated for 30 min at 32 C. 100 ll
of BIOMOL Green reagent (Enzo Life Sciences) was added to the
reaction followed by a 25 min incubation before measuring the
absorbance at 620 nm using an ELISA multiplate reader
(Sunrise, Tecan). The amount of phosphate released was calcu-
lated using a phosphate standard and used according to the
manufacturer’s instructions (Enzo Life Sciences).
Overexpression of ATAD3A in primary fibroblasts
Human ATAD3A cDNA was cloned into the pcDNA5 vector
(Invitrogen) using BamHI and XhoI restriction sites. Primers
used for amplification were: 5’-GCCGGATCCGGAATGTC
GTGGCTCTTCGGCATT-3’, and 5’-CGCCTCGAGTCAGGATGGGGA
GGGCTCGTC-3’. Site-directed mutagenesis was conducted to
introduce the G355D mutation with primers 5’-ATGTACGGG
CCACCAGACACCGGGAAGACG-3’, and 5’- CGTCTTCCCGGTGTC
TGG TGGCCCGTACAT-3’ using the Pfu polymerase (Thermo
Fisher). The plasmid sequences were verified by Sanger
sequencing. Primary human fibroblasts were cultured in DMEM/
FBS/L-Glutamine/Uridine in 37

C, 95% Oxygen, 5% CO2. Plasmid
transfections to the cells were conducted according to the
manufacturer’s instructions using jetPRIME in vitro DNA &
siRNA transfection reagent (Polyplus). Cells for immunocyto-
chemistry were co-transfected with mitochondria-targeted red
fluorescent protein (mito-Red) (pDsRed2-Mito Vector, Clontech)
or mito-GFP (pAcGFP1-Mito Vector, Clontech).
Cell culture and reprogramming
Primary fibroblasts were reprogrammed using the combination
of six factors (OCT3/4, SOX2, KLF4, L-MYC, LIN28 and T53
shRNA) in three episomal plasmids on matrigel coated plates
(39). The control line HEL11.4 has been thoroughly characterized
previously (40). For the characterisation of the patient’s iPSC
lines, immunocytochemistry and quantitative PCR were per-
formed (Supplementary Material, Fig. S3). For immunocyto-
chemistry the iPSC were fixed at room temperature with 4%
paraformaldehyde for 10 min. Non-specific proteins were
blocked by ultra V block (Thermo Fisher). Cells were then
treated with primary antibodies overnight at 4

C. Primary anti-
bodies against OCT4 (1:500, SC-9081; Santa Cruz Biotechnology),
SSEA4 (1:1000, MC-813-70; Millipore), and TRA-1-60 (1:500, MA1-
023; Thermo Fisher) were used to detect stem cell-specific
markers. After washing with PBS, cells were incubated with
fluorescence-conjugated secondary antibody Alexa Fluor 488:
donkey anti-rabbit (1:500, A21206; Thermo Fisher) and donkey
anti mouse (1:500, A21206; Thermo Fisher). The nuclei were
mounted with 4’,6-diamidino-2-phenylindole (Vectashield;
Vector Laboratories). For quantitative PCR total RNA was ex-
tracted from iPSC using a NucleoSpin RNA II kit (Macherey-
Nagel). DNA was digested in a separate reaction using DNaseI
(Promega). Two micrograms of RNA were used for reverse tran-
scription (RT) reaction that was performed using Moloney mur-
ine leukemia reverse transcriptase, random hexamers, and
oligoT (Promega) according to the manufacturer’s instructions.
The quantitative PCR reactions were carried out in a Corbette
thermal cycler (Qiagen). The relative expression levels of the
genes were calculated by calibrating their CT values with that of
the housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and normalized to human embryonic stem cell
line H9 (as reference sample). Primer sequences were as follows:
OCT3/4 (5’-TTGGGCTCGAGAAGGATGTG-3’ and 5’-TCCTCTCG
TTGTGCA TAGTCG-3’), SOX2 (5’-GCCCTGCAGTACAACTCCAT-3’
and 5’-TGCCCTGCTGCGAGTAGGA-3’), TDGF1 (5’-GAGATGACAG
CAT TTGGC-3’ and 5’-GGCAGCAGGTTCTGTTTA-3’), NANOG (5’-
CTCAGCCTCC AGCAGATGC-3’ and 5’-TAGATTTCATTCTCTG
GTTCTGG-3’), GAPDH (5’-GGTCATCCATGACAACTTTGG-3’ and
5’-TGAGCTTCCCGTTCAGCTC-3’). Episomal vectors were de-
tected by PCR using the following primers: EBNA1 (5’-ATC
GTCAAAGCTGCACACAG-3’ and 5’-CCCAGGAGTC CCAGT
AGTCA-3’) and oriP (5’-TTCCACGAGGGTAGTGAACC-3’ and 5’-
TCGGGGGTGTTAGAGA CAAC-3’).
iPSC-derived neuron differentiation
iPSC were cultured in Essential 8 basal medium (# A1516901,
Life Technology) with Essential 8 Supplement (50X, #1517101,
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Life Technology) on Matrigel (#356231, BD) coated plates. The
cells were differentiated into neurons as adherent cultures on
Poly-D-lysine and Laminin coated plates using an established
differentiation protocol (25). Briefly, the iPSC were detached
using 0.5mM EDTA (#15575, Life Technology) in PBS, then cells
were transferred to a suspension culture in 6-well plates
(CorningVR 3471 CostarVR ) to initiate the neurosphere stage. The
medium used for neurospheres contained DMEM/12,
Neurobasal media, GlutaMax, B27 supplement (50X), N2 supple-
ment (100X), and bFGF (40 mg/ml). After 4–6 weeks culturing, the
neurospheres were cut into monolayer cultures on Poly-D-
lysine (A-003-E, Merke Millipore) and Laminin (L2020, Sigma)
coated plates. Differentiated neurons were cultured in medium
containing DMEM/12, Neurobasal media, GlutaMax, B27 supple-
ment, and N2 supplement for 2 weeks, and neuronal identity
was confirmed with immunostaining using neuronal markers
MAP-2 and TUJ1.
Immunocytochemistry
The cells for immunocytochemistry were cultured on cover
glasses in 6-well plates. 24 h after transfection, the cells were
rinsed in PBS three times, fixed with 4% paraformaldehyde for
10 min at RT, rinsed in PBS three times, incubated in 0.2% Triton
100X in PBS for 15 min and rinsed in TBST (0.1% Tween-20 in
PBS) three times. Cells were blocked on coverslips for 2 h at RT
with 5% BSA/PBST and incubated in primary antibody for 90 min
at RT or overnight atþ4C. The following day, cells were washed
with PBST three times for 15 min, then incubated in secondary
antibody for 1 h at RT. After repeating washing with PBST three
times for 15 min, the cells were mounted with Vectashield
Mounting Media with DAPI (H-1200, Vector Laboratories).
Lysotracker quantification by flow cytometry
The Lysotracker Green signal was quantified using flow cytome-
try. Fibroblasts were incubated with 50nM Lysotracker Green
(Thermo Fisher Scientific) or vehicle (DMSO) for 30 min at 37 C
in 5% CO2, rinsed, trypsinised and collected in 1 ml of PBSþ 5%
FBS and filtered. The signal of ca. 20, 000 cells was counted for
each sample with a BD LSRFortessa flow cytometer exciting
with a 488nm laser. Background autofluorescence was corrected
for by measuring untreated cells.
Measurement by of mitochondrial membrane potential
Mitochondrial membrane potential was determined by quan-
tifying the signal of the fluorescent probe tetramethylrhod-
amine (TMRM). Fibroblasts were incubated with 200nM TMRM
(SigmaAldrich) in DMEM for 20 min at 37 C in 5% CO2, rinsed,
trypsinised and collected in 0.5 ml of PBSþ 5% FBS and filtered.
Cell suspensions were kept at 37 C until each measurement.
The signal of ca. 20,000 cells was counted for each sample with
a BD LSRFortessa flow cytometer exciting with a 488nm laser.
Background autofluorescence was corrected for by measuring
untreated cells.
Microscopy and confocal live cell imaging
After immunocytochemistry, cells were imaged with a Zeiss
Axio Observer microscope (Zeiss, Germany) with a 63X oil im-
mersion objective and Apotome.2. The excitation/emission
wavelengths (nm) used were: blue (DAPI), 350/461; green (GFP),
498/516; and red (DsRed), 558/583 or with a 3i (intelligent imag-
ing innovations) CSU-W1 confocal spinning disk microscope,
with a 100X oil immersion objective and an excitation/emission
wavelength (nm) of 490/525, green (GFP) and red (Dsred) 555/580
and images were captured with the Slidebook 6 software
(Intelligent Imaging Innovations). Cells were incubated with
MitoTracker-Red (MitoTrackerVR Red FM, M22425, Thermo) and
Lyso-Tracker-Green (LysoTrackerVR Green DND-26, L7526,
Thermo) for 15 min in the incubator. Live cell microscopy was
performed with a Zeiss LSM880 laser confocal microscope with
a 63X oil immersion objective for with the following excitation/
emission wavelengths (nm): blue (DAPI), 350/461; green (GFP),
498/516; and red (DsRed), 558/583. Images were captured with
Zeiss ZEN Pro software (Zeiss, Germany). Alternatively, cells
were imaged live with a Leica TCS SP5 confocal microscope with
the following excitation/emission wavelengths (nm): green
(GFP), 503/553, and red (DsRed), 570/620, and images were cap-
tured with the Las AF software (Leica). Statistical analyses were
done with Microsoft Excel and GraphPad Prism softwares.
Electron microscopy
The cells for electron microscopy were cultured on cover glass
in 6-well plates. The cells were washed two times with PBS,
then fixed in 2% glutaraldehyde and 2% formaldehyde for
30 min at 4 C and then left in 2% glutaraldehyde in PBS at RT.
Cells were embedded, and blocks were cut into thin sections
and stained with OsO4 according to the standard procedure of
the Laboratory of Electron Microscopy, University of Turku,
Finland. The grids were imaged with a JEOL JEM-1400 plus trans-
mission electron microscope equipped with an 11 Mpx Olympus
Quemesa digital camera.
Starvation and autophagy inhibition
Patient and control fibroblasts were separately kept in either fed
condition in normal medium (DMEM with FBS, L-Glutamine and
Uridine) or in a starved condition in HBSS (#24020117, Thermo
Fisher) for 4 h. The Bafilomycin-inhibitor (Baf, B1793, Sigma)
was used as a lysosomal inhibitor (100nM concentration) and
DMSO as a vehicle.
Western blotting
Cells were lysed for protein extraction by incubating for 5 min in
RIPA buffer (10X, #9806, Cell Signaling) on ice after washing with
PBS twice. Cells were then scraped and sonicated briefly, centri-
fuged for 10 min at 14,000x g inþ4C. Protein concentrations
were measured with Bradford or a Nanodrop 2000 instrument.
20–40mg of protein was run into a 10% or 12% polyacrylamide gel
(Bio Rad) at 100V for 10 min and then 150V for 50 min. Semi-dry
blotting (Thermo Fisher) was conducted transferring the pro-
teins to a PVDF transfer membrane (Merck Millipore) under
36mA for 65 min. Alternatively, proteins were transferred to a
nitrocellulose membrane (AmershamTM ProtanTM, GE
Healthcare Life Sciences) by wet blotting under 45 V for 15 min,
then 120 V for 45 min. 5% milk/TBST was used for blocking the
membrane for 1 h at RT followed by incubation with primary
antibodies overnight inþ4 C. On the following day, the mem-
brane was washed with TBST and incubated with secondary
antibody for 1 h at RT. After washing with TBST, ECL Prime
Detection Reagent (GE Healthcare) or ClarityTM Western ECL
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Substrate (BioRad) was used to detect the bands for imaging
with a Chemidoc XRSþMolecular Imager (Bio-Rad).
Antibodies
ATAD3A [1:3 (IF), 1:10 (WB)], ATAD3 [1:2000 (IF), 1:10000 (WB)],
p62 (1:5000, Abnova, H00008878-M01 clone 2C11), COXII (1:1000,
EPR 3314), GAPDH (1:1000, CST 14C10), LC3B (1:1500, NB600-
1384), b-Tubulin (1:1000, CST 2146), TUJ1 (1:1000, # MMS-435P,
BioLegend), Tom20 (1:500 ICC; Santa Cruz sc-11415), HRP anti-
rabbit (1:10000, Molecular Probes), HRP anti-mouse (1:10000,
Molecular Probes), HRP anti-rat (1:10000, Molecular Probes),
anti-rabbit 550 (1:1000, Molecular Probes), anti-mouse 488
(1:1000, Molecular Probes), mToR (1:1000, CST 2972), phospho-
mTOR (Ser2481) (1:1000, CST 2974), ULK1 (1:1000, CST 8054),
phospho-ULK1 (Ser757) (1:1000, CST 6888), S6 ribosomal protein
(1:500, CST 2317), phospho-S6 ribosomal protein (Ser235/236)
(1:1000, CST 4858), Drp1 (1:1000, Santa Cruz sc-271583), OXPHOS
antibody cocktail (1:250, Abcam, ab110413).
Supplementary Material
Supplementary Material is available at HMG online.
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